The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 12: 1873 - 1878

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.12.015

Clinical Research

The levels of CBX2 and TIM3 in salivary adenoid cystic carcinoma tissue and their relationship with clinical pathological features and prognosis

  • Xuan ZHANG ,
  • Zhenli LIU ,
  • Yongchao YANG ,
  • Sai MA ,
  • Bo LIU ,
  • Hongjuan LYU
Expand
  • Department of Stomatology，the First Affiliated Hospital of Hebei North University，Zhangjiakou 075000，Hebei，China

Received date: 2025-03-07

  Online published: 2025-07-02

Fold

Abstract

Objective To investigate CBX2 and TIM3 in salivary adenoid cystic carcinoma （SACC） tissue and their relationship with clinical pathological features and prognosis. Methods 80 patients with SACC who underwent surgical treatment in the First Affiliated Hospital of Hebei North University from January 2016 to January 2020 were selected. Immunohistochemistry was used to measure CBX2 and TIM3 in tissues. The relationship between CBX2 and TIM3 in SACC tissue and prognosis was discussed though Kaplan-Meier method. The factors influencing the prognosis of SACC were discussed using multivariate Cox regression. Results The positive rates of CBX2 and TIM3 in SACC tissues were clearly higher than those in normal glandular tissues adjacent to cancer （χ2 = 11.237， 8.229， P < 0.05）. The CBX2 and TIM3 were associated with nerve invasion and distant metastasis （P < 0.05）. After a 5-year follow-up， 26 cases died and 54 cases survived， with an overall 5-year survival rate of 67.50% （54/80）. The death group had higher positive rates of CBX2 and TIM3 in SACC tissues than the survival group （P < 0.05）. Patients with positive CBX2 and TIM3 in SACC tissues had clearly lower 5-year survival rate than patients with negative CBX2 and TIM3 （Log Rank χ2 = 6.564， 5.197， P < 0.05）. CBX2， TIM3 positivity， nerve invasion， and distant metastasis were risk factors affecting prognosis （P < 0.05）. Conclusion The positive expression of CBX2 and TIM3 in SACC tissues is closely related to the clinical pathological features and prognosis of patients.

Key words： salivary adenoid cystic carcinoma; CBX2; TIM3; clinical pathological features; prognosis

Cite this article

Xuan ZHANG , Zhenli LIU , Yongchao YANG , Sai MA , Bo LIU , Hongjuan LYU . The levels of CBX2 and TIM3 in salivary adenoid cystic carcinoma tissue and their relationship with clinical pathological features and prognosis[J]. The Journal of Practical Medicine, 2025 , 41(12) : 1873 -1878 . DOI: 10.3969/j.issn.1006-5725.2025.12.015

References

1 SALEH E， UKWAS A. Adenoid Cystic Carcinoma of Salivary Glands： A Ten-Year Review and an Assessment of the Current Management， Surgery， Radiotherapy， and Chemotherapy［J］. Int J Otolaryngol， 2023，2023（1）：1-8. doi:10.1155/2023/7401458
2 CANTù G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A： From aetiopathogenesis to diagnosis［J］. Acta Otorhinolaryngol Ital， 2021，41（3）：206-214. doi:10.14639/0392-100x-n1379
3 CHOWSILPA S， AN D， MALEKI Z. Adenoid cystic carcinoma cytology： Salivary gland and nonsalivary gland［J］. Diagn Cytopathol， 2020，48（12）：1282-1289. doi:10.1002/dc.24573
4 LIU X， YANG X， ZHAN C， et al. Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands： Where We Are and Where We Need to Go［J］. Front Oncol， 2020，10（1）：1-13. doi:10.3389/fonc.2020.01493
5 FANG Y， PENG Z， WANG Y， et al. Current opinions on diagnosis and treatment of adenoid cystic carcinoma［J］. Oral Oncol， 2022，130（1）：1-15. doi:10.1016/j.oraloncology.2022.105945
6 MICHAELIDES I， KüNZEL J， ETTL T， et al. Adenoid cystic carcinoma of the salivary glands： A pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis［J］. Eur Arch Otorhinolaryngol， 2023，280（6）：2937-2944. doi:10.1007/s00405-023-07884-3
7 XU X， LAI C， LUO J， et al. The predictive significance of chromobox family members in prostate cancer in humans［J］. Cell Oncol （Dordr）， 2024，47（4）：1315-1331. doi:10.1007/s13402-024-00929-7
8 PENG L， HUANG X， QING D， et al. MiR-30a-5p inhibits cell behaviors in esophageal cancer via modulating CBX2［J］. Mutat Res， 2023，826（1）：1-11. doi:10.1016/j.mrfmmm.2023.111818
9 LU C， TAN Y. Promising immunotherapy targets： TIM3， LAG3， and TIGIT joined the party［J］. Mol Ther Oncol， 2024，32（1）：2-13. doi:10.1016/j.omton.2024.200773
10 PALACIOS LM， PEYRET V， VIANO ME， et al. TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages： An Emerging Immunotherapeutic Target［J］. Biology （Basel）， 2022，11（11）：1-13. doi:10.3390/biology11111609
11 BAYAT P， MAHDAVI N， YOUNESPOUR S， et al. Interactive role of miR-29， miR-93， miR-205， and VEGF in salivary adenoid cystic carcinoma［J］. Clin Exp Dent Res， 2023，9（1）：112-121. doi:10.1002/cre2.678
12 WANG J， YANG B， ZHANG X， et al. Chromobox proteins in cancer： Multifaceted functions and strategies for modulation （Review）［J］. Int J Oncol， 2023，62（3）：1-12. doi:10.3892/ijo.2023.5484
13 HU CY， LI X， ZENG T， et al. Significance of chromobox protein （CBX） expression in diffuse LBCL［J］. Gene， 2022，813（1）：1-12. doi:10.1016/j.gene.2021.146092
14 SUN R， TU X， CHAN S， et al. CBX2 Deletion Suppresses Growth and Metastasis of Colorectal Cancer by Mettl3-p38/ERK MAPK Signalling Pathway［J］. J Cancer， 2024，15（8）：2123-2136. doi:10.7150/jca.92633
15 ZHU J， LUO J E， CHEN Y， et al. Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer［J］. J Ovarian Res， 2021，14（1）：1-13. doi:10.1186/s13048-021-00888-9
16 ZENG M， LI B， YANG L， et al. CBX2 depletion inhibits the proliferation， invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway［J］. Mol Med Rep， 2021，23（2）：137-146. doi:10.3892/mmr.2020.11776
17 LI W， SHI R， GAO Y， et al. CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness［J］. J Biol Chem， 2025，301（2）：1-10. doi:10.1016/j.jbc.2025.108170
18 朱元媛，闫洪超，刘永利，等. BTLA、LAG3和TIM3在上皮性卵巢癌组织中的表达意义［J］. 实用医学杂志，2019，35（5）：698-702.
19 ZHAO L， CHENG S， FAN L， et al. TIM-3： An update on immunotherapy［J］. Int Immunopharmacol， 2021，99（1）：1-13. doi:10.1016/j.intimp.2021.107933
20 KANDEL S， ADHIKARY P， LI G， et al. The TIM3/Gal9 signaling pathway： An emerging target for cancer immunotherapy［J］. Cancer Lett， 2021，510（1）：67-78. doi:10.1016/j.canlet.2021.04.011
21 SAUER N， JANICKA N， SZLASA W， et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors［J］. Cancer Immunol Immunother， 2023，72（11）：3405-3425. doi:10.1007/s00262-023-03516-1
22 YANG R， SUN L， LI C F，et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy［J］. Nat Commun， 2021，12（1）：832-845. doi:10.1038/s41467-021-21099-2
23 GARDNER A， DE MINGO PULIDO á， H?NGGI K， et al. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization［J］. J Immunother Cancer， 2022，10（1）：1-11. doi:10.1136/jitc-2021-003571
24 王辉，张利娟，杨芳. 半乳糖凝集素-9和T细胞免疫球蛋白黏蛋白分子3在口腔扁平苔藓和口腔鳞状细胞癌组织中的表达及临床意义［J］. 癌症进展，2020，18（6）：576-579.
25 田绣云，周美云，韩瑞，等. 涎腺腺样囊性癌的临床特征及预后分析［J］. 医学研究杂志，2023，52（6）：108-111，116.
Options
Outlines

/

〈 〉